Similar Items: Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis
- Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema
- Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden
- US Retina Specialists’ Preferences for Geographic Atrophy Treatment
- Rhegmatogenous Retinal Detachment Associated With a Retinal Tear Overlying a Choroidal Nevus
- Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
- Prism Success in Patients with Diplopia and Retinal Pathology